Welcome to our dedicated page for Global Innovative Platforms SEC filings (Ticker: GIPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Global Innovative Platforms's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Global Innovative Platforms's regulatory disclosures and financial reporting.
Global Innovative Platforms Inc. disclosed that major shareholder David A B Brown, acting as trustee for his IRA, made a series of open-market purchases of common stock. Across six transactions from October 2023 through June 2025, the IRA acquired a total of 6,682,800 shares, including multiple 250,000-share trades at $0.002 per share and a 2,000,000-share trade at $0.10 per share. Following the most recent purchase on June 30, 2025, Brown’s IRA indirectly holds 6,775,612 shares of Global Innovative Platforms common stock.
Global Innovative Platforms Inc. expanded its board of directors from one to four members, effective April 1, 2026, and appointed Elyssa Jacob Campbell, James C. Jones, Anthony (Tony) Porter, and David Mauer as directors.
The new directors bring experience in animal health research, legal practice, healthcare operations, business development, and partnership management, aligning with the company’s focus on innovative breath-based diagnostics for animal health. The company states there are no family relationships, appointment-related arrangements, or related-party transactions requiring disclosure, and that any committee assignments or director compensation will be detailed in a later filing.
Global Innovative Platforms Inc. reported its first revenues while remaining deeply loss-making and dependent on new funding. For the quarter ended March 31, 2026, the company generated $106,500 in revenue, all from a single animal-health customer using its VOCAM Plus diagnostic technology, and posted a net loss of $151,386. For the six-month period, revenue totaled $136,500 with a net loss of $200,815. Cash and cash equivalents rose to $327,270 and total assets to $591,958, largely funded by $514,354 of common stock proceeds, while liabilities stayed minimal at $2,284. The accumulated deficit reached $1,456,279, and management and the auditors highlight substantial doubt about the company’s ability to continue as a going concern without additional debt or equity financing. As of May 15, 2026, there were 49,103,241 common shares outstanding, reflecting continued equity issuance to investors and service providers.
Global Innovative Platforms Inc. submitted a Form 12b-25 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company states additional time is needed to complete financial statements, disclosures and allow review by its independent auditor, and expects to file the Form 10-Q in accordance with Rule 12b-25, no later than the fifth calendar day following the prescribed due date.
The notification is signed by Andrew Brown, Chief Executive Officer and dated May 18, 2026.
Global Innovative Platforms Inc. director Campbell Elyssa Jacob has filed an initial Form 3 showing beneficial ownership of 20000 shares of the company’s common stock. These shares are reported as held with direct ownership, and no derivative securities or buy/sell transactions are reported in this filing.
Global Innovative Platforms Inc. director Porter Ernest Anthony filed an initial Form 3, formally reporting his status as a director and his beneficial ownership position under Section 16 rules. The filing does not list any buy, sell, or derivative exercise transactions.
Global Innovative Platforms Inc. director Mauer David Michael has filed a Form 3 showing ownership of 20,000 shares of the company’s Common stock. These shares are listed as held directly, and the filing does not report any specific buy or sell transaction, only the holding amount.
Global Innovative Platforms Inc. posted an updated investor presentation on its website on March 31, 2026. The presentation, which is furnished as Exhibit 99.1, is available under the Investor Relations section of www.vetbreath.com.
The company states that the information in this report and Exhibit 99.1 is furnished under Regulation FD, not filed, and is therefore not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings.
Global Innovative Platforms Inc. reported its quarterly results for the three months ended December 31, 2025. The animal health diagnostics company generated its first revenue, recording $30,000 from a licensing and evaluation agreement for its Plus breath-analysis technology, but still posted a net loss of $49,429, improved from a $120,467 loss a year earlier. Operating expenses fell as research and development and general and administrative costs declined, helping narrow losses.
Cash and cash equivalents were $49,004 with total assets of $224,951 and current liabilities of $65,784, including $55,500 of deferred revenue tied to its new contract. Accumulated deficit reached $1,304,892, and management again disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting it will need additional debt or equity financing to fund operations and growth. As of February 17, 2026, 47,531,657 common shares were outstanding, reflecting ongoing equity issuance to fund the business.
Global Innovative Platforms Inc. is an early-stage animal health company developing non-invasive breath and air analytics, with an initial focus on a Heartworm Breath Test for dogs using licensed VOCAM Plus gas chromatography devices, FROG units, and Ellvin AI software from Defiant Technologies.
The company remains in research and development, recorded no revenue for the years ended September 30, 2025 and 2024, and reported a retained deficit of approximately $1.25 million, leading its auditors to include a going concern warning. It has billed and collected $85,000 after year-end but still expects to rely on additional debt or equity financing.
Global Innovative Platforms depends heavily on an exclusive license from Defiant for animal and agricultural applications, operates with minimal staff and basic cybersecurity measures, and trades as a thinly traded penny stock on the OTC Expert Market, exposing shareholders to liquidity and volatility risks.